It will come as no surprise to the well-informed that if you are taking a 5-alpha-reductase inhibitor (a 5-ARI) like dutasteride or finasteride for benign prostatic hyperplasia (BPH), it significantly lowers your “normal” PSA level (to about half the actual value). … READ MORE …
Filed under: Diagnosis, Risk | Tagged: 5-ARI, Diagnosis, dutasteride, finasteride, PSA, risk | 12 Comments »
Something that most of us seem to have managed to “miss” at the American Urological Association (AUA) annual meeting in San Francisco in May was an update from Dr. Ian Thompson on the 25-year outcomes of the Prostate Cancer Prevention Trial (PCPT). It has the potential to be rather important! … READ MORE …
Filed under: Diagnosis, Prevention, Risk | Tagged: Diagnosis, finasteride, Prevention, risk | 17 Comments »
Another study, just published in the British Medical Journal, appears to further debunk the idea that use of 5α-reductase inhibitors (5-ARIs) is associated with a significant increase in risk for development of high-grade prostate cancer. … READ MORE …
Filed under: Diagnosis, Prevention, Risk | Tagged: 5ARI, dutasteride, finasteride, Gleason, Prevention, risk | 2 Comments »
An article published today in the New England Journal of Medicine and based on a re-visitation of data from the Prostate Cancer Prevention Trial (PCPT) suggests that finasteride may prevent as many as 30 percent of cases of low-risk prostate cancer without any increase in mortality. … READ MORE …
Filed under: Diagnosis, Management, Prevention, Risk | Tagged: finasteride, mortality, Prevention, risk, trial | 13 Comments »
As is so often the case in medicine, data suggesting a positive finding from one study comes out at about the same time as data demonstrating exactly the opposite … and in prostate cancer this occurs all too frequently! … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention, Risk | Tagged: 5-ARI, benefit, dutasteride, finasteride, outcome, Prevention, risk | 39 Comments »
The Prostate Cancer Prevention Trial (PCPT) showed that treatment with finasteride (a 5α-reductase inhibitor) could lower the number of prostate cancers diagnosed in the U.S. each year by about 25 percent. … READ MORE …
Filed under: Diagnosis, Prevention, Risk | Tagged: death, finasteride, mortality, PCPT, Prevention, survival | 5 Comments »
The U.S. Food & Drug Adminstration (FDA), yesterday, issued a statement about modifications to the labeling (the product prescribing information) for the two branded formulations of finasteride: Propecia® (finasteride 1 mg) and Proscar® (finasteride 5 mg). These modifications to the product labeling may be relevant to some men with or at risk for prostate cancer. … READ MORE …
Filed under: Uncategorized | Tagged: adverse, effect, finasteride, side | Leave a comment »
Yesterday the US Food & Drug Administration (FDA) updated its guidance on the use of 5α-reductase inhibitors with specific reference to the risk that use of these products may be able to induce high-grade (and therefore high-risk) prostate cancer in a small subset of men treated with these agents. … READ MORE …
Filed under: Diagnosis, Prevention, Risk | Tagged: 5-ARI, dutasteride, FDA, finasteride, Prevention, risk | 4 Comments »
It is becoming increasingly clear that the prevention, treatment, and management of prostate cancer is at an intellectual as well as a practical, clinical crossroads. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention, Risk | Tagged: dutasteride, finasteride, Prevention, PSA, screening, supplement, testing, testosterone | 2 Comments »
A new clinical trial being run by some of the investigators who originally coordinated the Prostate Cancer Prevention Trial is investigating whether a brief period of finasteride therapy (“finasteride challenge”) can help to distinuish between patients at serious risk for prostate cancer and those who don’t even need a biopsy. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: biopsy, challenge, Diagnosis, finasteride, PSA, risk | Leave a comment »
A recent article in the Journal of General Internal Medicine argues that using 5α-reductase (5-ARI) therapy (i.e., with dutasteride or finasteride) to prevent the early onset of prostate cancer is not justified by the available data. … And we entirely agree, … READ MORE …
Filed under: Diagnosis, Prevention, Risk | Tagged: 5-ARI, dutasteride, finasteride, outcome, pomegranate, Prevention | 2 Comments »
We will presumably be at least a little wiser about this issue when data from the REDEEM trial are presented at the Genitourinary Cancers Symposium in Orlando on Thursday; however, data from Canada already suggest that 5α-reductase inhibitors (5-ARIs) affect progression of low-risk forms of prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: 5-ARI, active surveillance, dutasteride, finasteride, outcome, progression | 5 Comments »
Unfortunately — but far from unexpectedly — the Oncology Drugs Advisory Committee (ODAC) to the US Food & Drug Administration today voted against the approval of durasteride for the prevention of prostate cancer in men known to be at elevated risk. … READ MORE …
Filed under: Living with Prostate Cancer, Prevention | Tagged: dutasteride, finasteride, Prevention | 6 Comments »
The recent publication of an article on trends in the prescription of finasteride has re-stimulated the debate on the use of 5α-reductase inhibitors (5-ARIs) like finasteride and dutasteride in the prevention of prostate cancer. … READ MORE …
Filed under: Management, Prevention | Tagged: 5-ARIs, dutasteride, finasteride, Prevention | 2 Comments »
For years, some clinicians have been telling their patients to use a 5α-reductase inhibitors (5-ARIs) like finasteride or dutasteride as a form of “bridge” therapy to extend their periods of time off primary hormone therapy while being treated with intermittent hormone therapy or IHT. … READ MORE …
Filed under: Uncategorized | Tagged: 5-ARI, finasteride, IHT, intermiottent hormone therapy | 10 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 